

# Maximum Dosage and Frequency

Policy Number: 2022D0034AG

Effective Date: November 1, 2022

 [Instructions for Use](#)

Table of Contents	Page
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Applicable Codes</a> .....	14
<a href="#">Benefit Considerations</a> .....	19
<a href="#">Clinical Evidence</a> .....	19
<a href="#">References</a> .....	19
<a href="#">Policy History/Revision Information</a> .....	21
<a href="#">Instructions for Use</a> .....	24

Related Commercial Policies	
• <a href="#">Cimzia® (Certolizumab Pegol)</a>	
• <a href="#">Complement Inhibitors (Soliris® &amp; Ultomiris®)</a>	
• <a href="#">Denosumab (Prolia® &amp; Xgeva®)</a>	
• <a href="#">Entyvio® (Vedolizumab)</a>	
• <a href="#">Infliximab (Avsola™, Inflectra®, Remicade®, &amp; Renflexis®)</a>	
• <a href="#">Oncology Medication Clinical Coverage</a>	
• <a href="#">Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors</a>	
• <a href="#">Rituximab (Riabni™, Rituxan®, Ruxience®, &amp; Truxima®)</a>	
• <a href="#">RNA-Targeted Therapies (Amvuttra™ and Onpatro®)</a>	
• <a href="#">Stelara® (Ustekinumab)</a>	
• <a href="#">White Blood Cell Colony Stimulating Factors</a>	
• <a href="#">Xolair® (Omalizumab)</a>	

  

Community Plan Policy	
• <a href="#">Maximum Dosage and Frequency</a>	

## Coverage Rationale

 See [Benefit Considerations](#)

This policy provides information about the maximum dosage per administration and dosing frequency for certain medications administered by a medical professional. Most medications have a maximum dosage and frequency based upon body surface area or patient weight or a set maximal dosage and frequency independent of patient body size.

## Drug Products

- abatacept (Orencia®)
- afiblertcept (Eylea®)
- atezolizumab (Tecentriq®)
- avelumab (Bavencio®)
- bevacizumab (Avastin®)
- bevacizumab-awwb (Mvasi™)
- bevacizumab-bvzr (Zirabev®)
- bevacizumab-maly (Alymsys®)
- brolucizumab-dbll (Beovu®)
- cemiplimab-rwlc (Libtayo®)
- certolizumab pegol (Cimzia®)
- denosumab (Prolia® & Xgeva®)
- durvalumab (Imfinzi®)
- eculizumab (Soliris®)
- emicizumab-kxwh (Hemlibra®)
- golimumab (Simponi Aria®)
- infliximab (Remicade®)
- infliximab-axxq (Avsola™)
- infliximab-dyyb (Inflectra®)
- infliximab-abda (Renflexis®)
- ipilimumab (Yervoy®)
- nivolumab (Opdivo®)
- omalizumab (Xolair®)
- patisiran (Onpatro®)

- pegaptanib sodium (Macugen®)
- pegfilgrastim (Neulasta®)
- pegfilgrastim-apgf (Nyvepria™)
- pegfilgrastim-cbqv (Udenyca®)
- pegfilgrastim-jmdb (Fulphila™)
- pegfilgrastim-bmez (Zixtenzo®)
- pembrolizumab (Keytruda®)
- ranibizumab (Lucentis®)
- ravulizumab-cwvz (Ultomiris®)
- rituximab (Rituxan®)
- rituximab-pvrr (Ruxience™)
- rituximab-abbs (Truxima®)
- rituximab-arrx (Riabni™)
- rituximab and hyaluronidase (Rituxan Hycela®)
- testosterone cypionate (Depo-Testosterone®)
- testosterone enanthate
- testosterone pellets (Testopel®)
- testosterone undecanoate (Aveed®)
- tildrakizumab-asmn (Illumya™)
- tocilizumab (Actemra®)
- trastuzumab (Herceptin®)
- trastuzumab-anns (Kanjinti™)
- trastuzumab-dkst (Ogvrl™)
- trastuzumab-dttb (Ontruzant®)
- trastuzumab-pkrb (Herzuma®)
- trastuzumab-qyyp (Trazimera™)
- ustekinumab (Stelara®)
- vedolizumab (Entyvio®)
- zoledronic acid (zoledronic acid, Reclast®)

The use of medications included in this policy when given within the maximum dosage and/or frequency based upon body surface area or patient weight or a set of maximal dosage and/or frequency independent of patient body size are proven when used according to labeled indications or when otherwise supported by published clinical evidence.

The medications included in this policy when given beyond maximum dosages and/or frequency based upon body surface area or patient weight or a set maximal dosage independent of patient body size are not supported by package labeling or published clinical evidence and are unproven.

This policy creates an upper dose limit based on the clinical evidence and the 95<sup>th</sup> percentile for adult body weight (140 kg) and body surface area (2.71 meters<sup>2</sup>) in the U.S. (adult male, 30 to 39 years, Fryar, 2021).<sup>59</sup> In some cases, the maximum allowed units and/or vials may exceed the upper level limit as defined within this policy due to an individual patient body weight > 140 kg or body surface area > 2.71 meters<sup>2</sup>.

## Maximum Allowed Quantities by HCPCS Units

Medication Name		Maximum Dosage per Administration	HCPCS Code	Maximum Allowed
Brand	Generic			
Actemra	tocilizumab	800 mg	J3262	800 HCPCs units (1 mg per unit)
Alymsys	(bevacizumab-maly)	15 mg/kg	C9142	240 HCPCS units (10 mg per unit)
Avastin	bevacizumab	15 mg/kg	J9035	240 HCPCS units (10 mg per unit)
Mvasi	bevacizumab-awwb	15 mg/kg	Q5107	240 HCPCS units (10 mg per unit)
Zirabev	bevacizumab-bvzr	15 mg/kg	Q5118	240 HCPCS units (10 mg per unit)
Aveed	testosterone undecanoate	750 mg	J3145	750 HCPCs units (1 mg per unit)
Cimzia	certolizumab pegol	400 mg	J0717	400 HCPCS units (1 mg per unit)
N/A	testosterone enanthate	400 mg	J3121	400 HCPCs units (1 mg per unit)
Depo-Testosterone	testosterone cypionate	400 mg	J1071	400 HCPCs units (1 mg per unit)
Entyvio	vedolizumab	300 mg	J3380	300 HCPCS units (1 mg per unit)

Medication Name		Maximum Dosage per Administration	HCPCS Code	Maximum Allowed
Brand	Generic			
Hemlibra	emicizumab-kxwh	6mg/kg	J7170	1,680 HCPCs units (0.5 mg per unit)
Herceptin	trastuzumab	8 mg/kg	J9355	126 HCPCS units (10 mg per unit)
Herzuma	trastuzumab-pkrb	8 mg/kg	Q5113	126 HCPCS units (10 mg per unit)
Kanjinti	trastuzumab-anns	8 mg/kg	Q5117	126 HCPCS units (10 mg per unit)
Ogivri	trastuzumab-dkst	8 mg/kg	Q5114	126 HCPCS units (10 mg per unit)
Ontruzant	trastuzumab-dttb	8 mg/kg	Q5112	126 HCPCS units (10 mg per unit)
Trazimera	trastuzumab-qyyp	8 mg/kg	Q5116	126 HCPCS units (10 mg per unit)
Ilumya	tildrakizumab-asmn	100 mg	J3245	100 HCPCs units (1 mg per unit)
Neulasta	pegfilgrastim	6 mg	J2506	12 HCPCS unit (0.5 mg per unit)
Nyvepria	pegfilgrastim-apgf	6 mg	Q5122	12 HCPCS units (0.5mg per unit)
Fulphila	pegfilgrastim-jmdb	6 mg	Q5108	12 HCPCS units (0.5mg per unit)
Udenyca	pegfilgrastim-cbqv	6 mg	Q5111	12 HCPCS units (0.5mg per unit)
Ziextenzo	pegfilgrastim-bmez	6 mg	Q5120	12 HCPCS units (0.5mg per unit)
Opdivo	nivolumab	480 mg	J9299	480 HCPCS units (1 mg per unit)
Orencia	abatacept	1000 mg	J0129	100 HCPCs units (10 mg per unit)
Reclast	zoledronic acid	5 mg	J3489	5 HCPCS units (1 mg per unit)
Zoledronic Acid	zoledronic acid	5 mg	J3489	5 HCPCS units (1 mg per unit)
Avsola	infliximab-axxq	10 mg/kg	Q5121	150 HCPCS units (10 mg per unit)
Inflectra	infliximab-dyyb	10 mg/kg	Q5103	150 HCPCS units (10 mg per unit)
Remicade	infliximab	10 mg/kg	J1745	150 HCPCS units (10 mg per unit)
Renflexis	infliximab-abda	10 mg/kg	Q5104	150 HCPCS units (10 mg per unit)
Onpattro	patisiran	30 mg	J0222	300 HCPCS units (0.1 mg per unit)
Prolia	denosumab	60 mg	J0897	60 HCPCS units (1 mg per unit)

Medication Name		Maximum Dosage per Administration	HCPCS Code	Maximum Allowed
Brand	Generic			
Xgeva	denosumab	120 mg	J0897	120 HCPCS units (1 mg per unit)
Rituxan	rituximab	500mg/m <sup>2</sup>	J9312	150 HCPCS units (10 mg per unit)
Ruxience	rituximab-pvvr	500mg/m <sup>2</sup>	Q5119	150 HCPCS units (10 mg per unit)
Truxima	rituximab-abbs	500mg/m <sup>2</sup>	Q5115	150 HCPCS units (10 mg per unit)
Riabni	rituximab-arrx	500mg/m <sup>2</sup>	Q5123	150 HCPCS units (10 mg per unit)
Rituxan Hycela	rituximab and hyaluronidase	1,600 mg	J9311	160 HCPCs units (10 mg per unit)
Simponi Aria	golimumab	2 mg/kg	J1602	300 HCPCs units (1 mg per unit)
Soliris	eculizumab	1200 mg	J1300	120 HCPCS units (10 mg per unit)
Stelara	ustekinumab	90 mg	J3357	90 HCPCS units (1 mg per unit)
		520 mg	J3358	520 HCPCS units (1 mg per unit)
Testopel	testosterone pellet	450 mg	S0189	6 HCPCs units (75 mg per unit)
Ultomiris	ravulizumab-cwvz	3,600 mg	J1303	360 HCPCS units (10 mg per unit)
Xolair	omalizumab	600 mg	J2357	120 HCPCS units (5 mg per unit)
Bavencio	avelumab	800 mg	J9023	80 HCPCS units (10 mg per unit)
Imfinzi	durvalumab	1,500 mg	J9173	150 HCPCS units (10 mg per unit)
Keytruda	pembrolizumab	400 mg	J9271	400 HCPCS units (1 mg per unit)
Libtayo	cemiplimab-rwlc	350 mg	J9119	350 HCPCS units (1 mg per unit)
Tecentriq	atezolizumab	1,680 mg	J9022	168 HCPCS units (10 mg per unit)
Yervoy	ipilimumab	10 mg/kg	J9228	1400 HCPCS units (1 mg per unit)

## Maximum Allowed Quantities for National Drug Code (NDC) Billing

The allowed quantities in this section are calculated based upon both the maximum dosage information supplied within this policy as well as the process by which NDC claims are billed. This list may not be inclusive of all available NDCs for each drug product and is subject to change. Absence of a specific NDC does not mean that it is not subject to the following maximum allowed:

Medication Name		Diagnosis	How Supplied	National Drug Code	Maximum Allowed
Brand	Generic				
Actemra	tocilizumab		20 mg/mL vials	50242-0135-01 50242-0136-01 50242-0137-01	40 mL
			162 mg / 0.9 mL pre-filled syringe 162 mg / 0.9 mL pre-filled syringe autoinjector	50242-0138-01 50242-0143-01	0.9 mL
Avastin	bevacizumab		100 mg/4mL vials	50242-0060-01 50242-0060-10	12 mL
			400 mg/16 mL vials	50242-0061-01 50242-0061-10	96 mL
Mvasi	bevacizumab-awwb		100 mg/4mL vials	55513-0206-01	12 mL
			400 mg/16 mL vials	55513-0207-01	96 mL
Zirabev	bevacizumab-bvzr		100 mg/4mL vials	00069-0315-01	12 mL
			400 mg/16 mL vials	00069-0342-01	96 mL
Alymsys	bevacizumab-maly		100mg/4mL vials	70121-1754-01 70121-1754-07	12 mL
			400mg/16mL vials	70121-1755-01 70121-1755-07	96 mL
Aveed	testosterone undecanoate		750 mg/3 mL	67979-0511-43	3 mL
Cimzia	certolizumab pegol		2 x 200mg kit	50474-0700-62	2 vials
			2 x 200 mg/ml prefilled syringe (PFS) kit	50474-0710-79	2 mL
			6 x 200 mg/ml PFS kit	50474-0710-81	2 mL
N/A	testosterone enanthate		200 mg/mL	00143-9750-01 00574-0821-05 00591-3221-26	2 mL
Depo-Testosterone	testosterone cypionate		200 mg/mL	00009-0085-10 00009-0086-01 00009-0086-10 00009-0347-02 00009-0417-01 00009-0417-02 00009-0520-01 00009-0520-10 00143-9659-01 00143-9726-01 00409-6557-01 00409-6562-01 00409-6562-02 00409-6562-20 00409-6562-22 00517-1830-01 00574-0820-01 00574-0820-10 00574-0827-01 00574-0827-10 00591-4128-79	2 mL

Medication Name		Diagnosis	How Supplied	National Drug Code	Maximum Allowed
Brand	Generic				
				50090-0330-00 52536-0625-01 52536-0625-10 62756-0015-40 62756-0016-40 62756-0017-40 63874-1061-01 64980-0467-99 69097-0536-37 69097-0537-31 69097-0537-37 69097-0802-32 69097-0802-37 76420-0650-01 76519-1210-00	
Entyvio	vedolizumab		300 mg vial	64764-0300-20	1 vial
Hemlibra	emicizumab-kxwh		30 mg/mL	50242-0920-01	1 mL
			105 mg/0.7 mL	50242-0922-01	0.7 mL
			150 mg/mL	50242-0923-01	6 mL
			60 mg/0.4 mL	50242-0921-01	0.4 mL
				50242-0132-01 50242-0132-10	
Herceptin	trastuzumab		150 mg vial	50242-0132-01 50242-0132-10	8 vials
Herzuma	trastuzumab-pkrb		420 mg vial	63459-0305-47 63459-0307-41	3 vials
			150 mg vial	63459-0303-43	3 vials
				55513-0132-01 55513-0141-01	
Kanjinti	trastuzumab-anns		420 mg vial	67457-0847-44 67457-0845-50	3 vials
			150 mg vial	67457-0991-15	3 vials
				00006-5033-02 00006-5034-01 00006-5034-02	
Ogivri	trastuzumab-dkst		420 mg vial	00069-0305-01 00069-0306-01	3 vials
			150 mg vial	00069-0305-01 00069-0306-01	3 vials
				47335-0177-95	1 mL
Ontruzant	trastuzumab-dttb		150 mg vial	47335-0177-95	1 mL
			420 mg vial	47335-0177-95	1 mL
				55513-0190-01 55513-0192-01	
Trazimera	trastuzumab-qypy		420 mg vial	55513-0190-01 55513-0192-01	3 vials
Ilumya	tildrakizumab-asmn		100 mg/mL PFS	67457-0833-06	0.6 mL
Neulasta	pegfilgrastim		6 mg/0.6 mL PFS	70114-0101-01	0.6 mL
			6 mg/0.6 mL PFS with on-body Injector	70114-0101-01	0.6 mL
Nyvepria	pegfilgrastim-apgf		6 mg/0.6mL PFS	70114-0101-01	0.6 mL
Fulphila	pegfilgrastim-jmdb		6 mg/0.6mL PFS	70114-0101-01	0.6 mL
Udenyca	pegfilgrastim-cbqv		6 mg/0.6mL PFS	70114-0101-01	0.6 mL

Medication Name		Diagnosis	How Supplied	National Drug Code	Maximum Allowed
Brand	Generic				
Ziextenzo	pegfilgrastim-bmez		6 mg/0.6mL PFS	61314-0866-01	0.6 mL
Opdivo	nivolumab		100 mg/10 mL vials	00003-3774-12	40 mL
			120mg/12 mL vials	00003-3756-14	48 mL
			240 mg/24 mL vials	00003-3734-13	48 mL
			40 mg/4 mL vials	00003-3772-11	8 mL
Onpattro	patisiran		10 mg/5 mL vials	71336-1000-01	15 mL
Orencia	abatacept		250 mg vials	00003-2187-10 00003-2187-13	4 vials
Remicade	infliximab		100 mg vials	57894-0030-01	14 vials
Avsola	infliximab-axxq		100 mg vials	55513-0670-01	14 vials
Renflexis	infliximab-abda		100 mg vials	00006-4305-01 00006-4305-02	14 vials
Inflectra	infliximab-dyyb		100 mg vials	00069-0809-01	14 vials
Rituxan	rituximab		100 mg/10 mL vials	50242-0051-10 50242-0051-21	40 mL
			500 mg/50 mL vials	50242-0053-06	150 mL
Ruxience	rituximab-pvvr		100 mg/10 mL vials	00069-0238-01	40 mL
			500 mg/50 mL vials	00069-0249-01	150 mL
Truxima	rituximab-abbs		100 mg/10 mL vials	63459-0103-10	40 mL
			500 mg/50 mL vials	63459-0104-50	150 mL
Riabni	rituximab-arrx		100 mg/10 mL vials	55513-0224-01	40 mL
			500 mg/50 mL vials	55513-0326-01	150 mL
Rituxan Hycela	rituximab and hyaluronidase		1,400-23, 400 mg/11.7 mL	50242-0108-01	1 vial
			1,600-26, 800 mg/13.4 mL	50242-0109-01	1 vial
Simponi Aria	golimumab		50 mg/4 mL	57894-0350-01	24 mL
Soliris	eculizumab	PNH	300 mg/30 mL vials	25682-0001-01	90 mL
		aHUS	300 mg/30 mL vials	25682-0001-01	120 mL
		MG	300 mg/30 mL vials	25682-0001-01	120 mL
Stelara	ustekinumab		45 mg/0.5 mL PFS	57894-0060-03	0.5 mL
			45 mg/0.5 mL vials	57894-0060-02	0.5 mL
			90 mg/1 mL PFS	57894-0061-03	1 mL
		Crohn's Disease	130 mg/26 mL vials	57894-0054-27	104 mL
		Ulcerative Colitis	130 mg/26 mL vials	57894-0054-27	104 mL
Testopel	Testosterone pellet		75 mg pellet	66887-0004-01 66887-0004-10 66887-0004-20	6 pellets
Ultomiris	ravulizumab-cwvz		300 mg/3 mL vials	25682-0025-01	9 mL
			1,100 mg/11 mL vials	25682-0028-01	44 mL

Medication Name		Diagnosis	How Supplied	National Drug Code	Maximum Allowed
Brand	Generic				
Xolair	omalizumab	Asthma	150 mg vials	50242-0040-62	3 vials
			150 mg/1 mL PFS	50242-0215-01	2 mL
			75 mg/0.5 mL PFS	50242-0214-01	0.5 mL
		Chronic Urticaria	150 mg vials	50242-0040-62	2 vials
			150 mg/1 mL PFS	50242-0215-01	2 mL
		Nasal Polyps	150 mg vials	50242-0040-62	4 vials
			150 mg/1 mL PFS	50242-0215-01	4 mL
			75 mg/ 0.5 mL PFS	50242-0214-01	0.5 mL
Prolia	denosumab	Osteoporosis	60 mg/1 mL PFS	55513-0710-01	1 mL
Xgeva	denosumab	Oncology	120 mg/1.7 mL vials	55513-0730-01	1.7 mL
Reclast	zoledronic acid		4 mg/5 mL vials	00409-4215-01 00409-4215-05 16714-0815-01 16729-0242-31 23155-0170-31 25021-0801-66 43598-0330-11 51991-0065-98 54288-0100-01 55111-0685-07 55150-0266-05 63323-0961-98 67457-0390-54 68001-0366-22 68001-0366-25	5 mL
			4 mg/100 mL vials	70860-0210-51	100 mL
			4 mg/100 mL infusion	00409-4229-01 23155-0186-31 25021-0826-67 25021-0826-82	100 mL
			5mg/100 mL vials	00078-0435-61 25021-0830-82 43598-0331-11 51991-0064-98 55111-0688-52 63323-0966-00 67457-0619-10	100 mL
			5 mg/100 mL infusion	00409-4228-01 25021-0830-82 67457-0794-10 70860-0802-82	100 mL
Bavencio	avelumab		200mg/10mL vials	44087-3535-01	40 mL
Imfinzi	durvalumab		120 mg/2.4 mL vials	00310-4500-12	9.6 mL
			500 mg/10 mL vials	00310-4611-50	30 mL

Medication Name		Diagnosis	How Supplied	National Drug Code	Maximum Allowed
Brand	Generic				
Keytruda	pembrolizumab		50 mg vials	00006-3029-01 00006-3029-02	8 vials
			100 mg/4 mL vials	00006-3026-01 00006-3026-02 00006-3026-04	16 mL
Libtayo	cemiplimab-rwlc		350mg/7mL vials	61755-0008-01	7 mL
Tecentriq	atezolizumab		840mg/14mL vials	50242-0918-01	28 mL
			1200mg/20mL vials	50242-0917-01	40 mL
Yervoy	ipilimumab		50mg/10mL vials	00003-2327-11	30 mL
			200mg/40mL vials	00003-2328-22	280 mL

## Maximum Allowed Frequencies

The allowed frequencies in this section are based upon the FDA approved prescribing information for the applicable medications. For indications covered by Oxford Health Plans without FDA approved dosing, the frequencies are derived from available clinical evidence. This list may not be inclusive of all medications listed and is subject to change.

Medication Name		Diagnosis	Maximum Frequency	
Brand	Generic			
Actemra	tocilizumab	PJIA, Rheumatoid Arthritis	Administered once every 4 weeks.	
		SJIA	Administered once every 2 weeks.	
		Cytokine release syndrome, Chimeric antigen receptor T-cell induced, severe or life threatening disease	Administer once, then if no improvement in signs and symptoms, may give up to 3 additional doses at least 8 hours apart.	
Alymsys	bevacizumab-maly	Oncology	Administered once every 2 weeks.	
Avastin	bevacizumab	Choroidal neovascularization secondary to pathologic myopia, angioid streaks/pseudoxanthoma elasticum, or ocular histoplasmosis syndrome	The recommended dose is 1.25 mg (0.05 mL) near-monthly into affected eyes during the first 12 months, with fewer injections needed in subsequent years. Maximum of 12 doses per year per eye.	
		Diabetic macular edema		
		Macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)	The recommended dose is 1.25 mg (0.05 mL) near-monthly into affected eyes during the first 12 months, with fewer injections needed in subsequent years. Maximum of 12 doses per year per eye.	
		Neovascular age-related macular degeneration		
		Neovascular glaucoma		
		Neovascularization of the iris (rubeosis iridis)		

Medication Name		Diagnosis	Maximum Frequency
Brand	Generic		
		Proliferative diabetic retinopathy	Administered once every 2 weeks.
		Type I retinopathy of prematurity	
		Oncology	
Aveed	testosterone undecanoate		The recommended dose is 750mg initially, followed by 750mg after 4 weeks, then 750mg every 10 weeks thereafter.
Bavencio	avelumab	Oncology	Administered once every 2 weeks.
Beovu	brolucizumab	Neovascular age-related macular degeneration	The recommended dose is 6 mg (0.05 mL) into affected eye(s) once monthly (approximately every 25 to 31 days) for the first 3 doses, then 6 mg every 8 to 12 weeks thereafter. Maximum of 12 doses per year per eye.
		Diabetic macular edema	The recommended dose is 6 mg (0.05 mL) into affected eye(s) every six weeks (approximately every 39 to 45 days) for the first 5 doses, then 6 mg every 8 to 12 weeks thereafter. Maximum of 12 doses per year per eye.
Byooviz	ranibizumab-nuna	Neovascular age-related macular degeneration	The recommended dose is 0.5 mg (0.05 ML) administered by intravitreal injection once a month (approximately 28 days). Patients may be treated with 3 monthly doses followed by less frequent dosing. Patients may also be treated with one dose every 3 months after 4 monthly doses. Maximum of 12 doses per year per eye.
		Macular Edema Following Retinal Vein Occlusion (RVO)	The recommended dose is 0.5 mg (0.05 ML) administered by intravitreal injection once a month (approximately 28 days). Maximum of 12 doses per year per eye.
		Myopic Choroidal Neovascularization (mCNV)	The recommended dose is 0.5 mg (0.05 ML) administered by intravitreal injection once a month (approximately 28 days) for up to 3 months.
Cimzia	Certolizumab pegol	Crohn's Disease	Administered initially, and at weeks 2, 4, then every 4 weeks thereafter.
		Ankylosing spondylitis, axial spondyloarthritis, plaque psoriasis (BW ≤ 90 kg), psoriatic arthritis, rheumatoid arthritis	Administered initially, and at weeks 2, 4, then every other/ every 2 weeks thereafter.
		Plaque Psoriasis (BW > 90kg)	Administered every other week.
N/A	testosterone enanthate		For replacement therapy, the suggested dosage is 50 mg to 400 mg every 2 to 4 weeks, not to exceed 400 mg per 14 days.
Depo-testosterone	testosterone cypionate		For replacement in the hypogonadal male, the suggested dosage is 50 mg to 400 mg every 2 to 4 weeks, not to exceed 400 mg per 14 days.
Entyvio	vedolizumab	Crohn's disease, ulcerative colitis	Administered at 0, 2, and 6 weeks, then every 8 weeks thereafter.
Eylea	afibercept	Diabetic macular edema	The recommended dose is 2 mg (0.05 mL) into affected eye(s) every 4 weeks (approximately every 28 days,
		Diabetic retinopathy	

Medication Name		Diagnosis	Maximum Frequency
Brand	Generic		
			monthly) for the first 20 weeks (5 months), then 2 mg every 8 weeks (2 months). Maximum of 12 doses per year per eye.
		Macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)	The recommended dose is 2 mg (0.05 mL) once every 4 weeks. Maximum of 12 doses per year per eye.
		Neovascular age-related macular degeneration	The recommended dose is 2 mg (0.05 mL) into affected eye(s) every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months). Maximum of 12 doses per year per eye.
Fulphila	pegfilgrastim-jmdb	Oncology	Administered once every 2 weeks.
Hemlibra	emicizumab-kxwh	Hemophilia A	3 mg/kg once weekly for the first 4 weeks, followed by maintenance dose of: <ul style="list-style-type: none"> <li>• 1.5 mg/kg once every week; or</li> <li>• 3 mg/kg once every 2 weeks; or</li> <li>• 6 mg/kg once every 4 weeks</li> </ul>
Herceptin	trastuzumab	Oncology	Administered once every week.
Herzuma	trastuzumab-pkrb	Oncology	Administered once every week.
Ilumya	tildrakizumab-asmn	Plaque Psoriasis	Administered at weeks 0, 4, and every 12 weeks thereafter.
Imfinzi	durvalumab	Oncology	Administered once every 2 weeks.
Avsola Inflectra Remicade Renflexis	infliximab-axxq infliximab-dyyb infliximab infliximab-abda	Ankylosing Spondylitis	Administered at 0, 2, and 6 weeks, then every 6 weeks thereafter.
		Crohn's disease, noninfectious uveitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis	Administered at 0, 2, and 6 weeks, then every 8 weeks thereafter.
		Sarcoidosis	Administered at week 0 and 2, then once every 4 to 6 weeks thereafter.
		Rheumatoid Arthritis	Administered at 0, 2, and 6 weeks, then every 8 weeks thereafter. Maintenance treatment may be increased to as often as every 4 weeks.
Kanjinti	trastuzumab-anns	Oncology	Administered once every week.
Keytruda	pembrolizumab	Oncology	Administered once every 3 weeks.
Libtayo	cemiplimab-rwlc	Oncology	Administered once every 3 weeks.
Lucentis	ranibizumab	Choroidal neovascularization secondary to pathologic myopia, angioid streaks/pseudoxanthoma	The recommended dose is 0.5 mg to affected eye(s) once a month (approximately every 28 days) for up to 3 months. May be retreated if necessary. Maximum of 12 doses per year per eye.

Medication Name		Diagnosis	Maximum Frequency
Brand	Generic		
		elasticum, or ocular histoplasmosis syndrome	
		Diabetic macular edema	The recommended dose is 0.3 mg to affected eye(s) once a month (approximately every 28 days). Maximum of 12 doses per year per eye.
		Diabetic retinopathy	
		Macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)	The recommended dose is 0.5 mg to affected eye(s) once a month (approximately every 28 days). Maximum of 12 doses per year per eye.
		Neovascular age-related macular degeneration	The recommended dose is 0.5 mg to affected eye(s) once a month (approximately every 28 days). Treatment may be reduced to 3 once monthly doses, followed by an average of 4 to 5 injections over the subsequent 9 months. Maximum of 12 doses per year per eye.
Macugen	pegaptanib	Diabetic macular edema	The recommended dose is 0.3 mg to affected eye(s) near-monthly during the first 12 months, with fewer injections needed in subsequent years. Maximum of 12 doses per year per eye.
		Neovascular age-related macular degeneration	The recommended dose is 0.3 mg to affected eye(s) once every 6 weeks. Maximum of 12 doses per year per eye.
Mvasi	bevacizumab-awwb	Oncology	Administered once every 2 weeks.
Neulasta	pegfilgrastim	Oncology	Administered once every 2 weeks.
Nyvepria	pegfilgrastim-apgf	Oncology	Administered once every 2 weeks.
Ogivri	trastuzumab-dkst	Oncology	Administered once every week.
Onpattro	patisiran	Polyneuropathy from hATTR amyloidosis	Administered once every 3 weeks.
Ontruzant	trastuzumab-dttb	Oncology	Administered once every week.
Orencia	abatacept	JIA, psoriatic arthritis, rheumatoid arthritis	Administered intravenously at 0, 2, and 4 weeks, then once every 4 weeks thereafter. Administered subcutaneously once weekly.
		Graft-versus-host disease (GVHD) prophylaxis	Administered on day before transplantation, followed by a dose on Day 5, 14, and 28 after transplant.
Prolia	denosumab	Osteoporosis	Administered once every 6 months.
Simponi Aria	golimumab	Ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis	Administered at 0, 4, then every 8 weeks thereafter.
Soliris	eculizumab	aHUS, MG, NMOSD, PNH	Administered once weekly for 5 doses, then every 2 weeks thereafter.
Stelara	ustekinumab	Psoriasis, psoriatic arthritis	Administered subcutaneously – initially and 4 weeks later, then every 12 weeks thereafter.

Medication Name		Diagnosis	Maximum Frequency
Brand	Generic		
		Crohn's disease ulcerative colitis	Administered intravenously (IV) initially one time, then subcutaneously 8 weeks after the initial IV dose, then once every 8 weeks thereafter.
Tecentriq	atezolizumab	Oncology	Administered once every 2 weeks.
Testopel	testosterone pellet		The dosage guideline for the testosterone pellets for replacement therapy in androgen-deficient males is 150mg to 450mg subcutaneously every 3 to 6 months. The usual dosage is as follows: Implant two 75mg pellets for each 25mg testosterone propionate required weekly. Thus when a patient requires injections of 75mg per week, it is usually necessary to implant 450mg (6 pellets). With injections of 50mg per week, implantation of 300mg (4 pellets) may suffice for approximately three months.
Trazimera	trastuzumab-qyyp	Oncology	Administered once every week.
Udenyca	pegfilgrastim-cbqv	Oncology	Administered once every 2 weeks.
Ultomiris	ravulizumab-cwvz	aHUS, PNH	Administered initially, week 2, then once every 4 or 8 weeks thereafter, depending on body weight.
		MG	Administered initially, week 2, then once every 8 weeks thereafter.
Vabysmo	Faricimab	Neovascular age-related macular degeneration	The recommended dose is 6 mg by intravitreal injection every 4 weeks for the first 4 doses, followed by one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36, and 48; or 3) Weeks 20, 28, 36 and 44. Although most patients require dosing every 8 weeks, some patients may need dosing every 4 weeks. Maximum of 12 doses per year per eye.
		Diabetic macular edema	The recommended dose is one of the following regimens: 1) 6 mg administered by intravitreal injection every 4 weeks for at least 4 doses, followed by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on response; or 2) 6 mg administered every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injections at intervals of every 8 weeks over the next 28 weeks. Although most patients require dosing every 8 weeks, some patients may need dosing every 4 weeks. Maximum of 12 doses per year per eye.
Xgeva	denosumab	Oncology	Administered once every 4 weeks.
		Hypercalcemia of Malignancy	Administer every 4 weeks with additional doses on days 8 and 15 of the first month of therapy.
Xolair	omalizumab	Asthma	Administered once every 2 or 4 weeks, depending on body weight and IgE levels.
		Chronic Urticaria	Administered once every 4 weeks.
		Nasal Polyps	Administered once every 2 or 4 weeks, depending on body weight and IgE levels.
Yervoy	ipilimumab	Oncology	Administered once every 3 weeks.

Medication Name		Diagnosis	Maximum Frequency
Brand	Generic		
Ziextenzo	pegfilgrastim-bmez	Oncology	Administered once every 2 weeks.
Zirabev	bevacizumab-bvzr	Oncology	Administered once every 2 weeks.

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J0129	Injection, abatacept, 10 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug self-administered)
J0222	Injection, patisiran, 0.1 mg
J0717	Injection, certolizumab pegol, 1 mg (Code may be used when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
J0897	Injection, denosumab, 1 mg
J1071	Injection, testosterone cypionate, 1 mg
J1300	Injection, eculizumab, 10 mg
J1303	Injection, ravulizumab-cwzv, 10 mg
J1602	Injection, golimumab, 1 mg, for intravenous use
J1745	Injection, infliximab, excludes biosimilar, 10 mg
J2357	Injection, omalizumab, 5 mg
J2506	Injection, pegfilgrastim, 0.5 mg
J3121	Injection, testosterone enanthate, 1 mg
J3145	Injection, testosterone undecanoate, 1 mg
J3245	Injection, tildrakizumab, 1 mg
J3262	Injection, tocilizumab, 1 mg
J3357	Ustekinumab, for subcutaneous injection, 1mg
J3358	Ustekinumab, for intravenous injection, 1 mg
J3380	Injection, vedolizumab, 1 mg
J3489	Injection, zoledronic acid, 1 mg
J7170	Injection, emicizumab-kxwh, 0.5 mg
J9022	Injection, atezolizumab, 10 mg
J9023	Injection, avelumab, 10 mg
J9035	Injection, bevacizumab, 10 mg
J9119	Injection, cemiplimab-rwlc, 1 mg
J9173	Injection, durvalumab, 10 mg
J9228	Injection, ipilimumab, 1 mg
J9271	Injection, pembrolizumab, 1 mg
J9299	Injection, nivolumab, 1 mg

HCPCS Code	Description
J9311	Injection, rituximab 10 mg and hyaluronidase
J9312	Injection, rituximab, 10 mg
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
Q5108	Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg
Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (Nyvepria), 0.5 mg
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg
Q5114	Injection, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg
Q5116	Injection, trastuzumab-qypy, biosimilar, (Trazimera), 10 mg
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (Ruxience), 10 mg
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo), 0.5 mg
Q5121	Injection, infliximab-axxq, biosimilar, (Avsola), 10 mg
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
S0189	Testosterone pellet, 75 mg

National Drug Code	Description
50242-0135-01	Actemra 20 mg/mL vial
50242-0136-01	Actemra 200 mg/10 mL vial
50242-0137-01	Actemra 400 mg/20 mL vial
50242-0138-01	Actemra 162 mg / 0.9 mL pre-filled syringe
50242-0143-01	Actemra 162 mg / 0.9 mL pre-filled syringe autoinjector
70121-1754-01	Alymsys 100mg/4mL vial
70121-1754-07	Alymsys 100mg/4mL vial
70121-1755-01	Alymsys 400mg/16mL vial
70121-1755-07	Alymsys 400mg/16mL vial
50242-0060-01	Avastin 100 mg/4 mL vial
50242-0060-10	
50242-0061-01	Avastin 400 mg/16 mL vial
50242-0061-10	
67979-0511-43	Aveed 750 mg/3 mL vial
55513-0670-01	Avsola 100 mg vial
44087-3535-01	Bavencio 200mg/10mL vial
50474-0700-62	Cimzia 2 x 200mg kit
50474-0710-79	Cimzia 2 x 200mg/ml prefilled syringe (PFS) kit
50474-0710-81	Cimzia 6 x 200 mg/ml PFS kit

National Drug Code	Description
00574-0821-05	testosterone enanthate 200 mg/mL vial
00143-9750-01	
00591-3221-26	
00517-1830-01	Depo-Testosterone (testosterone cypionate) 200 mg/mL vial
52536-0625-10	
52536-0625-01	
64980-0467-99	
69097-0802-32	
69097-0802-37	
00574-0827-01	
76519-1210-00	
00009-0086-01	
00009-0417-01	
00009-0520-01	
69097-0536-37	
69097-0537-31	
69097-0537-37	
50090-0330-00	
00409-6562-02	
00409-6562-22	
00143-9659-01	
62756-0017-40	
62756-0016-40	
00409-6557-01	
00409-6562-01	
00409-6562-20	
76420-0650-01	
00591-4128-79	
00009-0085-10	
00009-0086-10	
00574-0827-10	
00009-0520-10	
00009-0347-02	
62756-0015-40	
00143-9726-01	
00009-0417-02	
63874-1061-01	
00574-0820-01	
00574-0820-10	
64764-0300-20	Entyvio 300 mg vial
67457-0833-06	Fulphila 6 mg/0.6 mL PFS
50242-0922-01	Hemlibra 105mg/0.7 L
50242-0923-01	Hemlibra 150mg/mL
50242-0920-01	Hemlibra 30 mg/mL
50242-0921-01	Hemlibra 60 mg/0.4 mL

National Drug Code	Description
50242-0132-01	Herceptin 150 mg vial
50242-0132-10	
63459-0303-43	Herzuma 150 mg vial
63459-0305-47	Herzuma 420 mg vial
47335-0177-95	Ilumya 100mg/mL PFS
00310-4500-12	Imfinzi 120 mg/2.4 mL vial
00310-4611-50	Imfinzi 500 mg/10 mL vial
00069-0809-01	Inflectra 100 mg vial
55513-0141-01	Kanjinti 150 mg vial
55513-0132-01	Kanjinti 420 mg vial
00006-3029-01	Keytruda 50 mg vial
00006-3029-02	
00006-3026-01	Keytruda 100 mg/4 mL vial
00006-3026-02	
00006-3026-04	
61755-0008-01	Libtayo 350mg/7mL vial
55513-0206-01	Mvasi 100 mg/4 mL vial
55513-0207-01	Mvasi 400 mg/16 mL vial
55513-0190-01	Neulasta 6 mg/0.6 mL PFS
55513-0192-01	Neulasta 6 mg/0.6 mL PFS with on-body injector
00069-0324-01	Nyvepria 6 mg/0.6 mL PFS
67457-0991-15	Ogivri 150 mg vial
67457-0847-44	Ogivri 420 mg vial
67457-0845-50	
71336-1000-01	Onpattro 10 mg/5 mL vial
00006-5033-02	Ontruzant 150 mg vial
00003-3774-12	Opdivo 100 mg/10 ml vial
00003-3756-14	Opdivo 120mg/12 mL vials
00003-3734-13	Opdivo 240 mg/24 ml vial
00003-3772-11	Opdivo 40 mg/4 mL vial
00003-2187-10	Orencia 250 mg vial
00003-2187-13	
55513-0710-01	Prolia 60 mg/1 mL PFS
00078-0435-61	Reclast 5 mg/100 mL solution in vial
35356-0351-01	Reclast 5 mg/100 mL solution in vial
57894-0030-01	Remicade 100 mg vial
00006-4305-01	Renflexis 100 mg vial
00006-4305-02	
55513-0224-01	Riabni 100 mg/10 mL vial
55513-0326-01	Riabni 500 mg/50 mL vial
50242-0051-10	Rituxan 100 mg/10 mL vial
50242-0051-21	

National Drug Code	Description
50242-0053-06	Rituxan 500 mg/50 mL vial
50242-0108-01	Rituxan Hycela 1,400-23, 400 mg/11.7 mL vial
50242-0109-01	Rituxan Hycela 1,600-26, 800 mg/13.4 mL vial
00069-0238-01	Ruxience 100 mg/10 mL vial
00069-0249-01	Ruxience 500 mg/50 mL vial
57894-0350-01	Simponi Aria 50 mg/4 mL vial
25682-0001-01	Soliris 300 mg/30 mL vial
57894-0054-27	Stelara 130 mg/26 mL vial
57894-0060-03	Stelara 45 mg/0.5 mL PFS
57894-0060-02	Stelara 45 mg/0.5 mL vial
57894-0061-03	Stelara 90 mg/1 mL PFS
50242-0918-01	Tecentriq 840mg/14mL vial
50242-0917-01	Tecentriq 1200mg/20mL vial
66887-0004-01	Testopel 75 mg pellet
66887-0004-10	
66887-0004-20	
00069-0305-01	Trazimera 420 mg vial
00069-0306-01	
63459-0103-10	Truxima 100 mg/10 mL vial
63459-0104-50	Truxima 500 mg/50 mL vial
70114-0101-01	Udenyca 6 mg/0.6 mL PFS
25682-0025-01	Ultomiris 300 mg/3 mL vial
25682-0028-01	Ultomiris 1,100 mg/11 mL vial
55513-0730-01	Xgeva 120 mg/1.7 mL vial
50242-0215-01	Xolair 150 mg PFS
50242-0214-01	Xolair 75 mg PFS
00003-2327-11	Yervoy 50mg/10mL vials
00003-2328-22	Yervoy 200mg/40mL vials
61314-0866-01	Ziextenzo 6 mg/0.6 mL PFS
00069-0315-01	Zirabev 100 mg/4 mL vial
00069-0342-01	Zirabev 400 mg/16 mL vial
00409-4229-01 23155-0186-31 25021-0826-67 25021-0826-82	Zoledronic Acid 4 mg/100 mL infusion
70860-0210-51	Zoledronic Acid 4 mg/100 mL vial
00409-4215-01 00409-4215-05 16714-0815-01 16729-0242-31 23155-0170-31 25021-0801-66 43598-0330-11	Zoledronic Acid 4 mg/5 mL vial

National Drug Code	Description
51991-0065-98 54288-0100-01 55111-0685-07 55150-0266-05 63323-0961-98 67457-0390-54 68001-0366-22 68001-0366-25	
00409-4228-01 25021-0830-82 67457-0794-10 70860-0802-82	Zoledronic Acid 5 mg/100 mL infusion
00078-0435-61 25021-0830-82 43598-0331-11 51991-0064-98 55111-0688-52 63323-0966-00 67457-0619-10	Zoledronic Acid 5 mg/100 mL vial

## Benefit Considerations

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. Refer to the Policy and Procedure addressing the treatment of serious rare diseases.

## Clinical Evidence

The aforementioned pharmaceuticals all have dosing parameters that support a maximum dosage per body weight or body surface area or a set maximal dosage independent of patient body size. These maximum doses are product-specific, and in some cases, disease state-specific and are defined in the U.S. Food and Drug Administration (FDA) approved product prescribing information and/or in national compendia and other peer reviewed resources. This policy creates an upper dose limit based on the clinical evidence and the 95<sup>th</sup> percentile for adult body weight (140 kg) and body surface area (2.71 meters<sup>2</sup>) in the U.S. (adult male, 30 to 39 years, Fryar, 2021).<sup>59</sup>

Clinical evidence supports the use of the medications listed in this policy up to maximum dosages based upon body surface area or patient weight, when used according to labeled indications or when otherwise supported by published clinical evidence.

Clinical evidence does not support the use of the medications listed in this policy beyond maximum dosages based upon body surface area or patient weight. Use of these agents beyond such established maximum dosages adds significantly to risk of adverse events without conferring additional clinical benefit.

## References

- Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; February 2022.

2. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; January 2021.
3. Aveed [prescribing information]. Malvern, PA: Endo Pharmaceuticals; August 2021.
4. Avsola [prescribing information]. Thousand Oaks, CA: Amgen, Inc.; September 2021.
5. Beovu® [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; May 2022.
6. Cimzia [prescribing information]. Smyrna, GA: UCB, Inc.; September 2019.
7. Depo-testosterone [prescribing information]. New York, NY: Pharmacia & Upjohn Co.; August 2018.
8. Entyvio [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; June 2022.
9. Eylea® [prescribing information]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; June 2021.
10. Fulphila [prescribing information]. Rockford, IL: Mylan Institutional, LLC, October 2021.
11. Hemlibra [prescribing information]. South San Francisco, CA: Genentech, Inc.; June 2022.
12. Herceptin [package insert]. South San Francisco, CA: Genentech, Inc.; February 2021.
13. Herzuma [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; May 2019.
14. Ilumya [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2020.
15. Inflectra [prescribing information]. New York, NY: Pfizer Labs; March 2022.
16. Kanjinti [package insert]. Thousand Oaks, CA: Amgen Inc.; October 2019.
17. Lucentis® [prescribing information]. South San Francisco, CA; Genentech, Inc.; March 2018.
18. Macugen® [prescribing information]. San Dimas, CA; Gilead Sciences, Inc.; July 2016.
19. Mvasi [package insert]. Thousand Oaks CA: Amgen Inc.; November 2021.
20. Neulasta [prescribing information]. Thousand Oaks, CA: Amgen Inc.; February 2021.
21. Nyvepria [prescribing information]. Lake Forest, IL: Pfizer Oncology; October 2021
22. Ogviri [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; February 2021.
23. Onpattro [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; July 2022.
24. Ontruzant [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021.
25. Orencia [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co.; December 2021.
26. Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, May 2022.
27. Prolia [prescribing information]. Thousand Oaks, CA: Amgen Inc.; May 2022.
28. Reclast [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2017.
29. Remicade [prescribing information]. Horsham, PA: Janssen Biotech Inc.; October 2021.
30. Renflexis [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; January 2022.
31. Rituxan [prescribing information]. South San Francisco, CA: Genentech, Inc.; December 2021.
32. Rituxan Hycela [prescribing information]. South San Francisco, CA: Genentech, Inc.; June 2021.
33. Ruxience [prescribing information]. New York, NY: Pfizer Labs; November 2021.
34. Simponi Aria [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; February 2021.
35. Soliris [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; November 2020.
36. Stelara [prescribing information]. Horsham, PA: Janssen Biotech, Inc. August 2022.
37. Testopel [prescribing information]. Malvern, PA: Endo Pharmaceuticals, Inc.; August 2018.
38. Trazimera [package insert]. New York, NY: Pfizer Inc.; November 2020.
39. Truxima [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; February 2022.
40. Udenyca [prescribing information]. Redwood City, CA: Coherus BioSciences, Inc, June 2021.

41. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; April 2022.
42. Xgeva [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2020.
43. Xolair [prescribing information]. South San Francisco, CA: Genentech, Inc., July 2021.
44. Zixtenzo [prescribing information]. Princeton, NJ: Sandoz, Inc.; March 2021.
45. Zirabev [package insert]. New York, NY: Pfizer Inc.; May 2021.
46. Zometa [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.
47. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020.
48. Constantine S. Tam, Susan O'Brien, William Wierda, Hagop Kantarjian, Sijin Wen, Kim-Anh Do, Deborah A. Thomas, Jorge Cortes, Susan Lerner, and Michael J. Keating. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. *Blood* 2008; 112: 975-980.
49. Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric Reference Data for Children and Adults: United States, 2011-2014. *Vital Health Stat 3*. 2016 Aug;(39):1-46.
50. Reimbursement Codes [database online]. Rocky Hill, CT: RJ Health Systems International, LLC.; 2020.
51. Bavencio [package insert]. Rockland, MA: EMD Serono, Inc.; November 2020.
52. Imfinzi [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2021.
53. Keytruda [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; March 2022.
54. Libtayo [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; February 2021.
55. Tecentriq [package insert]. South San Francisco, CA: Genentech, Inc.; January 2022.
56. Yervoy [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; February 2022.
57. Riabni [package insert]. Thousand Oaks, CA: Amgen, Inc.; December 2020.
58. Alymsys [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2022.
59. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. *Vital Health Stat 3*(46). 2021.

## Policy History/Revision Information

Date	Summary of Changes
11/01/2022	<p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"> <li>● Revised list of medications requiring administration by a medical professional:           <ul style="list-style-type: none"> <li>○ Added (with corresponding maximum dosage and frequency limitations):               <ul style="list-style-type: none"> <li>■ Atezolizumab (Tecentriq®)</li> <li>■ Avelumab (Bavencio®)</li> <li>■ Bevacizumab-Maly (Alymsys®)</li> <li>■ Cemiplimab-Rwlc (Libtayo®)</li> <li>■ Durvalumab (Imfinzi®)</li> <li>■ Ipilimumab (Yervoy®)</li> <li>■ Pembrolizumab (Keytruda®)</li> <li>■ Rituximab-Arrx (Riabni™)</li> </ul> </li> <li>○ Removed Zometa®</li> </ul> </li> <li>● Updated language pertaining to body weight and surface area measurements to reflect the most recent clinical evidence</li> </ul> <p><b>Maximum Allowed Quantities by HCPCS Units</b></p> <ul style="list-style-type: none"> <li>● Revised list of applicable medications:           <ul style="list-style-type: none"> <li>○ Added:               <ul style="list-style-type: none"> <li>■ Alymsys® (bevacizumab-maly)</li> <li>■ Bavencio (avelumab)</li> <li>■ Imfinzi (durvalumab)</li> </ul> </li> </ul> </li> </ul>

Date	Summary of Changes
	<ul style="list-style-type: none"> <li>▪ Keytruda (pembrolizumab)</li> <li>▪ Libtayo (cemiplimab-rwlc)</li> <li>▪ Riabni (rituximab-arrx)</li> <li>▪ Tecentriq (atezolizumab)</li> <li>▪ Yervoy (ipilimumab)</li> <li>○ Removed Zometa®</li> <li>● Updated <i>Maximum Allowed</i> units for: <ul style="list-style-type: none"> <li>○ Avastin</li> <li>○ Avsola</li> <li>○ Hemlibra</li> <li>○ Herceptin</li> <li>○ Herzuma</li> <li>○ Inflectra</li> <li>○ Kanjinti</li> <li>○ Mvasi</li> <li>○ Ogivri</li> <li>○ Ontruzant</li> <li>○ Remicade</li> <li>○ Renflexis</li> <li>○ Rituxan</li> <li>○ Ruxience</li> <li>○ Trazimera</li> <li>○ Truxima</li> <li>○ Zirabev</li> </ul> </li> <li>● Updated <i>Maximum Dosage per Administration</i> for: <ul style="list-style-type: none"> <li>○ Rituxan</li> <li>○ Ruxience</li> <li>○ Truxima</li> </ul> </li> <li>● Removed list of applicable diagnoses for the following medications (retained only the highest maximum dosage/allowed units per HCPCS code): <ul style="list-style-type: none"> <li>○ Prolia (denosumab)</li> <li>○ Soliris (eculizumab)</li> <li>○ Stelara (ustekinumab)</li> <li>○ Xgeva (denosumab)</li> <li>○ Xolair (omalizumab)</li> <li>○ Zoledronic Acid</li> </ul> </li> </ul> <p><b>Maximum Allowed Quantities for National Drug Code (NDC) Billing</b></p> <ul style="list-style-type: none"> <li>● Revised list of applicable medications: <ul style="list-style-type: none"> <li>○ Added: <ul style="list-style-type: none"> <li>▪ Alymysys (bevacizumab-maly)</li> <li>▪ Bavencio (avelumab)</li> <li>▪ Imfinzi (durvalumab)</li> <li>▪ Keytruda (pembrolizumab)</li> <li>▪ Libtayo (cemiplimab-rwlc)</li> <li>▪ Riabni (rituximab-arrx)</li> <li>▪ Tecentriq (atezolizumab)</li> <li>▪ Yervoy (ipilimumab)</li> </ul> </li> <li>○ Removed Zometa®</li> </ul> </li> <li>● Updated applicable NDCs for: <ul style="list-style-type: none"> <li>○ Actemra: Added 50242-0138-01 and 50242-0143-01</li> <li>○ Ilumya: Removed 47335-0177-96, 47335-0177-01, and 47335-0177-10</li> <li>○ Opdivo: Added 00003-3756-14</li> <li>○ Ultomiris: <ul style="list-style-type: none"> <li>▪ Added 25682-0028-01 and 25682-0025-01</li> </ul> </li> </ul> </li> </ul>

Date	Summary of Changes
	<ul style="list-style-type: none"> <li>▪ Removed 25682-0022-01</li> <li>○ Xolair: <ul style="list-style-type: none"> <li>▪ Added 50242-0040-62</li> <li>▪ Removed 50242-0040-86 and 50242-0215-86</li> </ul> </li> <li>● Updated <i>Maximum Allowed</i> units for: <ul style="list-style-type: none"> <li>○ Avastin</li> <li>○ Avsola</li> <li>○ Hemlibra</li> <li>○ Herceptin</li> <li>○ Inflectra</li> <li>○ Mvasi</li> <li>○ Remicade</li> <li>○ Renflexis</li> <li>○ Rituxan</li> <li>○ Ruxience</li> <li>○ Truxima</li> <li>○ Zirabev</li> </ul> </li> </ul> <p><b>Maximum Allowed Frequencies</b></p> <ul style="list-style-type: none"> <li>● Revised list of applicable medications: <ul style="list-style-type: none"> <li>○ Added: <ul style="list-style-type: none"> <li>▪ Alymsys (bevacizumab-maly)</li> <li>▪ Bavencio (avelumab)</li> <li>▪ Byooviz (ranibizumab-nuna)</li> <li>▪ Herceptin (trastuzumab)</li> <li>▪ Herzuma (trastuzumab-pkrb)</li> <li>▪ Imfinzi (durvalumab)</li> <li>▪ Kanjinti (trastuzumab-anns)</li> <li>▪ Keytruda (pembrolizumab)</li> <li>▪ Libtayo (cemiplimab-rwlc)</li> <li>▪ Mvasi (bevacizumab-awwb)</li> <li>▪ Ogivri (trastuzumab-dkst)</li> <li>▪ Ontruzant (trastuzumab-dttb)</li> <li>▪ Tecentriq (atezolizumab)</li> <li>▪ Trazimera (trastuzumab-qyyp)</li> <li>▪ Vabysmo (faricimab)</li> <li>▪ Yervoy (ipilimumab)</li> <li>▪ Zirabev (bevacizumab-bvzr)</li> </ul> </li> </ul> </li> <li>● Added <i>Maximum Frequency</i> guidelines for: <ul style="list-style-type: none"> <li>○ Actemra for the diagnosis of “cytokine release syndrome, Chimeric antigen receptor T-cell induced, severe or life-threatening disease”</li> <li>○ Avastin for the diagnosis of “oncology”</li> <li>○ Beovu for the diagnosis of “diabetic macular edema”</li> <li>○ Orencia for the diagnosis of “graft-versus-host disease (GVHD) prophylaxis”</li> <li>○ Ultomiris for the diagnosis of “myasthenia gravis (MG)”</li> <li>○ Xgeva for the diagnosis of “hypercalcemia of malignancy”</li> </ul> </li> <li>● Revised <i>Maximum Frequency</i> guidelines for: <ul style="list-style-type: none"> <li>○ Avsola, Inflectra, Remicade, and Renflexis for the diagnosis of “sarcoidosis”: Replaced “administered at 0, 2, and 6 weeks, then every 8 weeks thereafter” with “administered at week 0 and 2, then once every 4 to 6 weeks thereafter”</li> <li>○ Hemlibra: Added language to clarify the listed <i>Maximum Frequency</i> guidelines apply to the diagnosis of “hemophilia A”</li> <li>○ Orencia for the diagnoses of “JIA, psoriatic arthritis, rheumatoid arthritis”: Replaced “administered at 0, 2, and 4 weeks, then once every 4 weeks thereafter” with “administered</li> </ul> </li> </ul>

Date	Summary of Changes
	<p><i>intravenously at 0, 2, and 4 weeks, then once every 4 weeks thereafter; administered subcutaneously once weekly</i></p> <ul style="list-style-type: none"> <li>○ Ultomiris: Replaced “administered initially, week 2, then once every 8 weeks thereafter” with “administered initially, week 2, then once every 4 or 8 weeks thereafter, depending on body weight”</li> </ul> <p><b>Applicable Codes</b></p> <ul style="list-style-type: none"> <li>● Added HCPCS codes J9022, J9023, J9119, J9173, J9228, J9271, and Q5123</li> <li>● Added NDCs 00003-2327-11, 00003-2328-22, 00003-3756-14, 00006-3026-01, 00006-3026-02, 00006-3026-04, 00006-3029-01, 00006-3029-02, 00310-4500-12, 00310-4611-50, 25682-0025-01, 25682-0028-01, 44087-3535-01, 50242-0138-01, 50242-0143-01, 50242-0917-01, 50242-0918-01, 55513-0224-01, 55513-0326-01, 61755-0008-01, 70121-1754-01, 70121-1754-07, 70121-1755-01, and 70121-1755-07</li> <li>● Removed NDCs 25682-0022-01, 47335-0177-96, 50242-0040-86, and 50242-0215-86</li> </ul> <p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>● Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information</li> <li>● Archived previous policy version 2022D0034AF</li> </ul>

## Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.